Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Economics of Cancer Care
Patient-Reported Outcomes More Common in EU Labeling than FDA Labeling of Drug Approved for Lung Cancer
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
A study comparing patient-reported outcomes (PROs) labeling claims in Europe and in the United States showed that the European Medicines Agency (EMA) is more proactive in considering patient-generated feedback in their drug labeling decisions—this despite the US Food and Drug Administration (FDA)’s 2009 guidance that emphasized the importance of gathering and disseminating such data.
Read Article
Urologists’ Prescribing of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer Vary by Practice Affiliation
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
An analysis comparing the prescribing habits of urology practices shows that, despite treatment guideline recommendations to the contrary, gonadotropin-releasing hormone (GnRH) agonists, which are only indicated for the palliative treatment of advanced prostate cancer, are routinely prescribed for patients with localized, low- or intermediate-grade prostate cancer, particularly by urologists who have no practice affiliation with a medical school.
Read Article
Single, Older Women Less Likely to Receive Guideline- Recommended Treatment for Breast Cancer in Rural Georgia
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
;Researchers looking at whether guideline-directed adjuvant treatments for breast cancer were actually being administered in rural areas of the United States found that only 41% of the patients in this study received all of the suggested treatment modalities for breast cancer.
Read Article
Use of High-Cost Tests for Lung Cancer Surveillance Rising
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
The use of costly diagnostic imaging of uncertain value is increasing rapidly for patients with localized non–small-cell lung cancer (NSCLC), according to data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database.
Read Article
Cancer Support Program Documents Savings
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
May 2013, Vol 4, No 4
A case management program for terminally ill patients with cancer can reduce cancer-related healthcare costs and extend hospice length of stay, according to an analysis of the Cancer Support Program (CSP) of Optum Health, a health services company, which was presented at the 2013 National Comprehensive Cancer Network
®
annual conference.
Read Article
Neoadjuvant Chemotherapy Reduces Costs for Older Patients with Ovarian Cancer
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
May 2013, Vol 4, No 4
Neoadjuvant chemotherapy for older patients with ovarian cancer would save $19 million annually compared with primary debulking surgery, based on a new cost- model assessment
Read Article
Palliative Care Cost-Effective for Platinum-Resistant Ovarian Cancer
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
,
Palliative Care
May 2013, Vol 4, No 4
Early palliative care proved to be cost-effective and cost-saving versus routine end-of-life care for patients with recurrent platinum-resistant ovarian cancer, according to a decision-model analysis.
Read Article
Cumulative Financial Impact of Skeletal-Related Events on Patients with Breast Cancer Is Significant
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
November 2012, Vol 3, No 8
San Francisco, CA—In patients with breast cancer with bone metastases, skeletal-related events (SREs) are associated with high treatment costs. For example, the cumulative cost of treating 1 spinal cord compression exceeds $100,000, according to a new cost analysis presented at the 2012 Breast Cancer Symposium.
Read Article
A Rational Step in Holding Down Costs in Cancer Care
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
November 2012, Vol 3, No 8
The cost of cancer care matters; in fact, it matters so much that Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City has decided not to include in its formulary the newly approved drug ziv-aflibercept (Zaltrap), which was recently approved for use in patients with progressive metastatic colorectal cancer.
Read Article
Telemedicine Saves Time, Resources for Palliative Radiotherapy
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2012, Vol 3, No 7
Montreal, Canada—Telemedicine reduces time spent on new-patient consultations for palliative radiotherapy, according to a study presented at the 2012 World Cancer Congress.
Read Article
Page 8 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma